4.1 Article

Genetic analysis of impaired trimethylamine metabolism using whole exome sequencing

Journal

BMC MEDICAL GENETICS
Volume 18, Issue -, Pages -

Publisher

BMC
DOI: 10.1186/s12881-017-0369-8

Keywords

-

Funding

  1. Children's Hospital of Philadelphia Research Institute (Institutional Development Fund)
  2. National Organization for Rare Disorders (US), National Institute on Deafness and Other Communication Disorders [P30DC011735]
  3. Monell Chemical Senses Center (Monell Institutional Funds)
  4. Shenzhen Municipal Government of China [CXZZ20130517144604091]
  5. Shenzhen Key Laboratory of Genomics [CXB200903110066A]
  6. Guangdong Enterprise Key Laboratory of Human Disease Genomics [2011A060906007]

Ask authors/readers for more resources

Background: Trimethylaminuria (TMAU) is a genetic disorder whereby people cannot convert trimethylamine (TMA) to its oxidized form (TMAO), a process that requires the liver enzyme FMO3. Loss-of-function variants in the FMO3 gene are a known cause of TMAU. In addition to the inability to metabolize TMA precursors like choline, patients often emit a characteristic odor because while TMAO is odorless, TMA has a fishy smell. The Monell Chemical Senses Center is a research institute with a program to evaluate people with odor complaints for TMAU. Methods: Here we evaluated ten subjects by (1) odor evaluation by a trained sensory panel, (2) analysis of their urine concentration of TMA relative to TMAO before and after choline ingestion, and (3) whole exome sequencing as well as subsequent variant analysis of all ten samples to investigate the genetics of TMAU. Results: While all subjects reported they often emitted a fish-like odor, none had this malodor during sensory evaluation. However, all were impaired in their ability to produce > 90% TMAO/TMA in their urine and thus met the criteria for TMAU. To probe for genetic causes, the exome of each subject was sequenced, and variants were filtered by genes with a known (FMO3) or expected effect on TMA metabolism function (other oxidoreductases). We filtered the remaining variants by allele frequency and predicated functional effects. We identified one subject that had a rare loss-of-function FMO3 variant and six with more common decreased-function variants. In other oxidoreductases genes, five subjects had four novel rare single-nucleotide polymorphisms as well as one rare insertion/deletion. Novel in this context means no investigators have previously linked these variants to TMAU although they are in dbSNP. Conclusions: Thus, variants in genes other than FMO3 may cause TMAU and the genetic variants identified here serve as a starting point for future studies of impaired TMA metabolism.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available